Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3840716 | 0.97 | FBP1 (0.39) | FBP1CES2CES1TSHRHSD17B10 | |
| SCHEMBL72771 | 0.75 | — | — | |
| SCHEMBL3014863 | 0.75 | — | — | |
| SCHEMBL3843770 | 0.75 | — | — | |
| Bromide SCHEMBL1124451 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL9636987 | 0.73 | — | — | |
| Bromide SCHEMBL1022377 | 0.73 | — | — | |
| Bromide SCHEMBL8586526 | 0.68 | SLC6A3 (0.35) | FBP1CES2CES1TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL28465060 | 0.68 | — | — | |
| SCHEMBL3545 | 0.65 | L3MBTL1 (0.57) | FBP1HSD17B10NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1253152-B1 | METHOD OF CONVERTING FUNCTIONAL GROUP THROUGH HALOGEN-METAL EXCHANGE REACTION | BANYU PHARMA CO LTD (JP) | 2009-11-04 | — | — | EP | claimed |
| US-6946559-B2 | Replacing a halogen atom with an electrophilic group (e.g., a formyl group) using either a mixture of an organomagnesium halide and an alkyllithium or a reaction product of the two, such as trialkylmagnesium lithium | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-09-20 | — | — | US | claimed |
| EP-1253152-B1 | METHOD OF CONVERTING FUNCTIONAL GROUP THROUGH HALOGEN-METAL EXCHANGE REACTION | BANYU PHARMA CO LTD (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-7439535-B2 | Process for exchanging functional groups by halogen-metal exchange reaction | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-6946559-B2 | Replacing a halogen atom with an electrophilic group (e.g., a formyl group) using either a mixture of an organomagnesium halide and an alkyllithium or a reaction product of the two, such as trialkylmagnesium lithium | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-09-20 | — | — | US | disclosed |
| US-20050156336-A1 | Process for exchanging functional groups by halogen-metal exchange reaction | MSD K.K. (JP) | 2005-07-21 | — | — | US | disclosed |
| US-20030130511-A1 | Method of converting functional group through halogen-metal exchange reaction | MSD K.K. (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1253152-A1 | METHOD OF CONVERTING FUNCTIONAL GROUP THROUGH HALOGEN-METAL EXCHANGE REACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050156336-A1 | Process for exchanging functional groups by halogen-metal exchange reaction | SLC39A11, MLX, SLC39A14 | FBP1 2418/4885CES2 3375/4885CES1 3441/4885 |
| US-20030130511-A1 | Method of converting functional group through halogen-metal exchange reaction | MLX, HAX1, ZFX | FBP1 1802/4885CES2 4250/4885CES1 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.